- 关于盟科
- 科学研究
- 新闻中心
-
Contezolid: First Approval
Drugs / 2021View Publication
-
A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro
Antimicrob Agents Chemother / 2021View Publication
-
Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity
Chem Res Toxicol / 2021View Publication
-
In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe
Antimicrob Agents Chemother / 2020View Publication
-
Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers
Antimicrob Agents Chemother / 2020View Publication
-
Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent,in Chinese Patients
Clinical Therapeutics / 2020View Publication
-
Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis
Clinical Therapeutics / 2019View Publication
-
Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent
J Pharmacokinet Pharmacodyn / 2019View Publication
-
Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.
Clinical Therapeutics / 2018View Publication
-
In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis
Antimicrob Agents Chemother / 2018View Publication
-
Single- and Multiple-Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I Versus Linezolid in Healthy Adult Subjects
Antimicrob Agents Chemother / 2017View Publication
-
Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes
Drug Metab Dispos / 2015View Publication
- 科学研究
